Ribon Therapeutics Taps Sudha Parasuraman for Chief Medical Officer

Sudha Parasuraman has been appointed chief medical officer of cancer drug developer Ribon Therapeutics. She was most recently the chief medical officer of X4 Pharmaceuticals (NASDAQ: [[ticker:XFOR]]). Her experience also include positions at uniQure (NASDAQ: [[ticker:QURE]]), Novartis (NYSE: [[ticker:NVS]]) and Millennium Pharmaceuticals.

In other moves, Ribon named Edward “Tad” Stewart to serve as chief business officer. Stewart most recently worked as president and CEO of microbial therapies developer Commense. In January, Cambridge, MA-based Ribon raised $65 million in Series B funding to support the research and development of small molecule drugs intended to block enzymes that help cancer cells survive.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan